OptiBiotix Health inks agreement with jointly fund and carry out a research project involving its mi

0 51

OptiBiotix Health PLC (LON:OPTI) said it has reached an agreement with Fondazione Edmund Mach – Centro Ricerca e Innovazione (FEM), based in Trento, Italy, and the University of Southampton, to jointly fund and carry out a research project examining the role of its microbiome products – LPLDL, SlimBiome/WellBiome –  to improve sleep, stress, and anxiety.

The life sciences company, which is developing compounds to tackle obesity, high cholesterol, diabetes and skincare, said the research includes the application of systems approaches to understand the far-reaching effects of microbiome modulators on the biomolecular system of the host and their implications for health and disease.

The agreement funds a PhD studentship to explore the potential of prebiotics – SlimBiome/ WellBiome – and probiotics – LPLD – for their ability to manage sleep, stress and anxiety.  The agreement includes a  double-blind, placebo-controlled, human study carried out during a period of stress-induced sleep disruption. 

READ: OptiBiotix Health grants US and Canada licence for LPLDL probiotic

Optibiotix said the research project will be performed in the School of Human Development and Health (HDH) in the Faculty of Medicine at the University of Southampton. HDH is internationally recognised for its multidisciplinary research in the area of nutrition and metabolism seeking to reduce the burden of non-communicable disease in both developed and developing countries.

The research follows on from a number of publications indicating a relationship between the gastrointestinal microbiota, neurobiochemistry, and emotional behaviour. It builds upon findings showing that prebiotics improved anxiety and depression in participants consuming ≥ 5 g/day, and probiotic consumption improved psychological or biological measures of depression, anxiety, or stress in individuals predisposed to a mood disorder.

A study by Costabile et al. in 2020 showed ingestion of 7.5 g per day of SlimBiome resulted in a statistically significant improvement in mood after 4 weeks (p = 0.0026).  

In a statement Stephen OHara, OptiBiotix Health CEO commented: “OptiBiotix has developed products based on a scientific understanding of their mechanisms of action and human studies which demonstrate safety and efficacy. These studies examine a range of parameters beyond the main study endpoint and have indicated a potential for opportunities beyond cardiovascular health for LPLDL, weight management for SlimBiome, and gut health for WellBiome.

“This agreement allows Optibiotix to explore the benefits of its existing products to help improve stress, anxiety and sleep disorders with world-leading scientists and academic institutions. Sleep aids and stress management products are the fastest-growing category within healthcare (Goldstein Market Intelligence, 2020). This is another step in extending the range of applications for OptiBiotix’s scientifically and clinically proven products into large growing markets where there is an unmet clinical need.”

Professor Jonathan Swann, University of Southampton added: “There is growing evidence for the bi-directional communication between the microbiota resident in the gut and biochemical processes and functions occurring in the brain. Such processes and functions can modulate cognition and emotional behaviour. This exciting project will apply high-resolution systems biology approaches to human studies exploring the potential for microbial modulators to improve stress, anxiety and sleep disorders.

“This will allow us to comprehensively characterise the impact of changes to the microbiome on its metabolic output and the biochemical flow to the human host. This information will help us to understand the biomolecular mechanisms underlying any potential changes in emotional behaviour. Such information will not only advance our knowledge in this field but will also assist in refining strategies to improve mental health.”

FEM is an academic research institute operating in the agri-food and environmental sectors. It is located in the Province of Trento in the Italian Dolomites and is the first “One Health” research centre in Italy. Within the Department of Food Quality and Nutrition at FEM, the Nutrition and Nutrigenomics Unit (NNU) has internationally recognised expertise in probiotics, prebiotics, polyphenols and functional foods.

The NNU mission is to measure how microbiomes along the food chain can be harnessed to improve food nutritional quality, food sustainability and improve human health. NNU has a special interest in fermented foods (especially fermented dairy products), functional ingredients, whole plant foods, their bioactive fractions (fibers, prebiotics and polyphenols) and probiotics.

Dr Keiran Tuohy, Fondazione Edmund Mach commented: “Disrupted sleep and sleep apnea are recognised risk factors of poor metabolic health and cardiovascular risk and are closely related to stress. Recent research has identified an important role for the gut microbiota and specific probiotic strains in regulating not just circadian rhythms and the gut clock, but also in building resilience to emotional stress.

“Metabolites produced by gut bacteria from certain foods (e.g. prebiotic fibers or amino acids like glutamate or tryptophan) or through co-metabolism of bile acids produced in the liver, are thought to underpin communication along the gut:brain axis. Moreover, many of these same metabolites regulate inflammation and cellular metabolism, two processes intricately linked to cardiovascular risk. This project aims to screen a panel of probiotic strains and prebiotics for their ability to produce molecules linked to cell signalling processes in the gut and systemically related to regulation of circadian rhythm, brain function, stress, inflammation and energy metabolism.”

Leave A Reply

Your email address will not be published.